Reverse Aging Phenomenon: Decoding Real Science Behind The Hype

In September 2015, a 44-year-old biotech CEO flew to Colombia and let doctors inject her with two experimental gene therapies that had never been tested in a human being.

She did this to herself. On purpose. Without FDA approval, because the FDA would never have approved it.

Her name was Elizabeth Parrish. Six months later, blood tests appeared to show that her telomeres, the protective caps on the ends of her chromosomes, had lengthened by the equivalent of 20 years. She called herself patient zero in the fight against aging itself.

Reverse aging is the idea that the biological processes responsible for getting older are not fixed and irreversible, but can, at least partially, be slowed, stopped, or run backward. It is no longer a fringe idea confined to longevity podcasts. It is now a serious, well-funded, and increasingly well-evidenced area of biomedical research, pursued by Harvard professors, FDA-cleared clinical trials, and billion-dollar laboratories.

This article covers where that research actually stands. The real studies. The real institutions. The real controversy. And the story of the woman who decided not to wait for any of it.

The stakes extend well beyond vanity. Aging is the single largest shared risk factor behind heart disease, cancer, dementia, and diabetes combined, and age-related disease accounts for trillions of dollars in annual healthcare spending in the United States alone. If even a handful of the interventions below prove out in large human trials, the effect on global healthspan would dwarf the impact of curing any single disease in isolation. That is the scale of ambition driving the laboratories, billionaires, and self-experimenters in this story.

Who Is Elizabeth Parrish, and What Did She Actually Do?

Elizabeth Parrish founded a small biotech company called BioViva, based on Bainbridge Island near Seattle. The company’s stated mission was to treat aging itself as a disease, rather than as the unavoidable backdrop to disease.

In September 2015, Parrish received two of her own company’s experimental therapies. The first was a myostatin inhibitor, intended to protect against age-related muscle loss. The second was a telomerase gene therapy, intended to lengthen telomeres and counteract the cellular aging associated with their shortening.

The procedure was done outside the United States specifically to avoid the regulatory process that would otherwise have been required. This drew sharp criticism from much of the biotech community, who argued that self-experimentation outside any clinical trial framework was reckless and scientifically meaningless, no matter how it turned out.

Six months later, BioViva reported that blood samples taken by an independent testing laboratory showed Parrish’s telomeres had lengthened from 6.71 kilobases to 7.33 kilobases. According to the company, this implied her white blood cells had become biologically younger by roughly 20 years.

The results were never published in a peer-reviewed scientific journal. They came from a single person, with no control group, no blinding, and no independent replication. Critics, including many longevity researchers who otherwise supported the broader goal of treating aging, pointed out that one telomere measurement before and after a treatment proves very little on its own.

What it did prove, whether or not the biology held up to scrutiny, was that someone was willing to bet her own body on the idea that aging could be reversed. According to a ten-year retrospective published in 2026, BioViva has since expanded its work well beyond telomerase, now targeting a broader set of genes including klotho, follistatin, FGF21, and partial reprogramming factors. Parrish did not deliver a cure. She did force a speculative idea into public conversation, and kept it there for a decade.

Bryan Johnson: A Decade Later, a Different Kind of Self-Experiment

Parrish was not the last person to turn her own body into a research project. A decade later, tech entrepreneur Bryan Johnson took a far more systematic, far more expensive version of the same idea and turned it into a media phenomenon.

Johnson, who sold his payment company Braintree to PayPal for 800 million dollars in 2013, launched Project Blueprint in 2021. Rather than a single gene therapy, Blueprint is an enormous, continuously adjusted stack of diet, exercise, sleep, supplements, and medical monitoring, costing him roughly two million dollars a year and overseen by a team of more than 30 physicians.

Johnson reports a biological age, measured through epigenetic clocks including DunedinPACE and GrimAge, that runs several years behind his calendar age, with some organ-specific measurements showing even larger gaps. He publishes his blood panels and protocols openly, which has made him both the most transparent and the most scrutinised figure in this entire field.

The scrutiny has been warranted in places. Johnson discontinued growth hormone therapy after it raised his intracranial pressure and blood glucose. He removed rapamycin from his stack in 2026 after side effects. A widely covered plasma exchange experiment, in which his teenage son donated plasma to him, showed no measurable benefit for Johnson himself, while plasma donated from Johnson to his 70-year-old father did appear to slow his father’s aging markers, an asymmetry that intrigued researchers more than the original headline did.

Independent critics, including the longevity supplement company NOVOS, have pointed out that other individuals using far cheaper, far less extreme protocols have posted larger biological age reductions on the same epigenetic tests. Oliver Zolman, a physician who formerly led Johnson’s medical team, has since argued publicly that the field’s credibility depends on separating genuine clinical evidence from bad medical advice circulating on social media.

Taken together, Parrish and Johnson represent two very different bets on the same idea, one through a single irreversible act in 2015, the other through an open-ended, constantly revised experiment running for years in public view. Neither has produced peer-reviewed proof that their personal results generalise to anyone else. Both have undeniably pulled enormous public attention toward a field that, until recently, mostly lived in academic journals nobody outside it read.

What Does “Reversing Aging” Actually Mean?

Before going further, it helps to be precise about what scientists mean when they say aging can be reversed, because the phrase gets used loosely.

Your chronological age is simply how many years you have been alive. Nobody is claiming to reverse that. What researchers are targeting is biological age: a measure of how old your cells, tissues, and organs actually appear at the molecular level, based on markers like DNA methylation patterns, telomere length, and the accumulation of senescent cells.

Two people can share the same chronological age and have meaningfully different biological ages. This is precisely the territory explored in our coverage of centenarian genetics, where some individuals appear to age far more slowly than the calendar would suggest.

The tools used to measure biological age, most notably the Horvath epigenetic clock, are what make reverse aging research testable at all. Without a way to measure biological age independently of birth certificates, claims of “reversal” would be unfalsifiable. With it, researchers can show, in controlled studies, that a given intervention measurably moves the needle backward.

The Twelve Hallmarks of Aging: The Map Behind Every Method

Every intervention covered in this article is, whether its developers say so explicitly or not, aimed at one or more items on a specific scientific checklist.

In 2013, a team led by Spanish biochemist Carlos López-Otín published a paper in the journal Cell proposing nine hallmarks of aging, common cellular and molecular processes that drive aging across essentially all studied organisms. In 2023, the same team, now including Maria Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer, expanded the list to twelve in an updated Cell paper titled “Hallmarks of Aging: An Expanding Universe.”

The twelve hallmarks include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis, an imbalance in the body’s microbial communities.

This framework is not just an academic curiosity. It is the shared language that lets researchers compare wildly different interventions on equal footing. Partial reprogramming primarily targets epigenetic alterations. Hyperbaric oxygen therapy and senolytics primarily target telomere attrition and cellular senescence. Fasting primarily targets deregulated nutrient sensing and disabled macroautophagy. Plasma dilution primarily targets altered intercellular communication and chronic inflammation.

According to the 2023 update, no single hallmark acts alone. They reinforce each other, which is precisely why researchers increasingly favour combination approaches over any single silver-bullet intervention, and why the field has shifted its language from curing aging to intercepting it across multiple fronts simultaneously.

Partial Cellular Reprogramming: The Most Credible Frontier

If there is one approach that the scientific establishment takes most seriously, it is partial cellular reprogramming, built on a Nobel Prize-winning discovery from 2006.

That year, Shinya Yamanaka showed that introducing four specific proteins into an adult cell could reset it all the way back to an embryonic, pluripotent state. These four proteins, OCT4, SOX2, KLF4, and c-MYC, are collectively known as the Yamanaka factors, or OSKM.

Full reprogramming erases a cell’s identity entirely. A skin cell stops being a skin cell. This is useful for stem cell research, but useless and dangerous for treating a living, aging body, since fully reprogrammed cells can form tumours.

The breakthrough came when researchers, including David Sinclair’s laboratory at Harvard, discovered that briefly and partially activating just three of the four factors, leaving out the more tumour-associated c-MYC, could restore youthful function to old cells without erasing what kind of cell they were.

In a landmark 2020 study that made the cover of Nature, Sinclair’s team used this three-factor approach, OSK, to restore vision in mice with damaged optic nerves, reversing a form of vision loss that mimics glaucoma. The cells became biologically younger by epigenetic measures, without losing their identity as retinal neurons.

By 2024, a related team extended this further, using gene therapy to deliver OSK systemically in naturally aged mice rather than mice with an artificial accelerated-aging disease. The treated mice lived 109 percent longer on average than untreated controls, and showed improved frailty scores, meaning they were not just living longer but living better.

This is where the story moves from mice to people. In January 2026, the FDA cleared Sinclair’s company, Life Biosciences, to begin the first human clinical trial of partial epigenetic reprogramming, targeting patients with glaucoma and a rare condition called NAION that damages the optic nerve.

“Until recently, the best we could do was slow aging. New discoveries suggest we can now reverse it.”
— David A. Sinclair, Professor of Genetics, Harvard Medical School. Harvard / Aging press release, 12 July 2023.

The trial is explicitly focused on safety first. Restoring lost vision would be a secondary, hoped-for outcome. This is also an extremely well-funded race. Altos Labs, Retro Biosciences, and NewLimit, backed respectively by investment from Yuri Milner, Sam Altman, and Brian Armstrong, are all competing to bring some version of partial reprogramming into the clinic.

The Newest Breakthrough: Rewinding Aging With a Single Gene Switch

The most striking development since this field’s early milestones arrived in January 2026, and it points to a strategy even simpler than reprogramming.

An NIH-funded team led by Changhui Deng, Saul Villeda, and Hao Li at the University of California, San Francisco, published findings in the Proceedings of the National Academy of Sciences on 9 January 2026. Rather than activating the four Yamanaka factors, they searched for individual transcription factors — master-switch proteins that control how many other genes are expressed — capable of nudging old cells back toward a younger pattern of activity.

The team screened the top 200 candidate transcription factors one by one in aged human fibroblasts, then focused on four. Boosting two of them, called EZH2 or E2F3, or lowering two others, made the old cells multiply more and behave more youthfully, without damaging DNA or triggering cancer-associated changes.

Then they tested it in living animals. Raising EZH2 levels in the livers of aged mice shifted thousands of genes back toward their youthful state, reduced fat buildup and scarring, and improved glucose tolerance, with no sign of liver damage or cancer.

“By altering gene expression using the transcription factors we identified, old fibroblasts behaved as if they were younger, and improved the health of old mice.”
— Hao Li, University of California, San Francisco. NIH Research Matters, 3 March 2026.

The significance is strategic. If a single transcription factor can reverse multiple aging changes at once, the path to a practical therapy may be shorter than the multi-gene reprogramming approach suggests. It remains early, animal-stage work, but it is among the most promising directions in the field.

Hyperbaric Oxygen Therapy: Lengthening Telomeres With Pressurised Air

Long before gene therapy entered the picture, researchers in Israel found something unexpected while studying a far simpler intervention: pressurised oxygen.

Hyperbaric oxygen therapy, or HBOT, involves breathing concentrated oxygen inside a pressurised chamber. It has been used for decades to treat decompression sickness and wound healing. What researchers at Tel Aviv University and Shamir Medical Center wanted to know was whether it could do anything for aging itself.

In a 2020 clinical trial led by Professor Shai Efrati, 35 healthy adults aged 64 and older underwent 60 hyperbaric sessions over 90 days, with no other lifestyle, diet, or medication changes. Blood was drawn before, during, and after the protocol.

The results, published in the peer-reviewed journal Aging, showed telomere lengthening of more than 20 percent, reaching up to 38 percent in some immune cells studied. The same protocol reduced the proportion of senescent cells, the worn-out, zombie-like cells discussed in our coverage of telomeres and cellular aging, by up to 37 percent.

“Today telomere shortening is considered the ‘Holy Grail’ of the biology of aging.”
— Professor Shai Efrati, Tel Aviv University and Shamir Medical Center. Tel Aviv University / Sagol Center press release, 18 November 2020.

Fasting and Caloric Restriction: The Oldest Known Longevity Lever

Of every intervention discussed here, caloric restriction has the longest and most consistent evidence behind it, stretching back nearly a century of animal research.

The modern human-relevant version of this idea is largely the work of Valter Longo, director of the Longevity Institute at the University of Southern California. Longo studied under calorie-restriction pioneer Roy Walford at UCLA before developing what he calls the fasting-mimicking diet, or FMD.

The FMD is a five-day, low-calorie, low-protein, plant-based eating pattern designed to trick the body into a fasting state without requiring true water-only fasting. According to Longo, this triggers cellular cleanup processes, particularly autophagy, in which cells break down and recycle damaged internal components.

Longo’s laboratory has published a randomised clinical trial, analysed in Nature Communications in 2024, showing that cycling through the FMD periodically reduced markers of biological age and multiple risk factors associated with aging, diabetes, and cardiovascular disease.

“People become two and a half years younger.”
— Valter Longo, University of Southern California, describing biological-age changes in FMD trial participants. DOC 2025 conference, “Fueling Longevity” session.

The cellular mechanism runs through a small set of nutrient-sensing pathways that recur throughout this article. When calories are scarce, an energy sensor called AMPK activates, while a growth-promoting pathway called mTOR — the same target rapamycin inhibits — winds down. This flips cells from a growth-and-build mode into a maintenance-and-repair mode, switching on autophagy, the recycling of damaged components including worn-out mitochondria.

A family of proteins called sirtuins, which require a coenzyme called NAD+ to function, also become more active during fasting, which is why NAD+ precursor supplements are so often discussed alongside fasting protocols. This is also precisely why metformin and rapamycin are described as caloric restriction mimetics: they engage the same AMPK and mTOR machinery pharmacologically, attempting to capture some of fasting’s cellular benefits without anyone actually fasting.

A separate 2026 study reinforced how quickly diet can move these markers. Researchers at the University of Sydney, led by Caitlin Andrews and published in Aging Cell, found that adults aged 65 to 75 showed measurable reductions in biological age after following specific diets for just four weeks, though the authors cautioned it is not yet known whether the improvements last.

Young Blood, Diluted Blood, and an Accidental Discovery

The idea that young blood might rejuvenate old bodies has a strange and important history, one that mostly disproved itself on the way to a more useful discovery.

In 2005, researchers Irina and Michael Conboy at UC Berkeley surgically joined the circulatory systems of an old mouse and a young mouse, a technique called parabiosis. The old mouse showed genuine signs of rejuvenation.

This launched a wave of excitement, and a wave of companies, around the idea that specific youthful proteins in young blood were the active ingredient. Some companies began offering young plasma infusions directly to paying customers.

Then the Conboy lab ran a more careful follow-up. When they exchanged blood between young and old mice without physically joining the animals, the young mice got measurably worse, not better. Young blood circulating through old veins, on its own, did not rejuvenate anything.

This led to a different hypothesis entirely: that aging is driven less by a deficiency of youthful factors, and more by an accumulation of harmful ones. To test it, the Conboys simply diluted old plasma, replacing part of it with plain saline and albumin, a basic blood protein, without adding any young blood at all.

The diluted old mice showed rejuvenation across muscle, liver, and brain tissue, including increased birth of new neurons and reduced inflammation, published in the journal Aging in 2020. Dilution alone, with no young blood whatsoever, outperformed the original parabiosis result.

By 2022, the same approach was tested directly in humans through therapeutic plasma exchange, a long-established medical procedure normally used for autoimmune conditions. A study in GeroScience found that repeated sessions shifted ten distinct protein biomarkers toward a younger systemic profile. A 2025 follow-up trial from the Buck Institute, published in Aging Cell, found that plasma exchange lowered participants’ biological age by an average of 1.32 years, with some protocols showing reductions of up to 2.6 years, across 240 sessions with only one mild allergic reaction.

Repurposed Drugs: Metformin, Rapamycin, and Telomerase Activators

Some of the most discussed reverse aging candidates were not designed for aging at all. They were designed for diabetes and organ transplants, and researchers noticed their side effects looked suspiciously like slower aging.

Metformin has been prescribed for type 2 diabetes since the 1950s. Large observational studies have repeatedly found that diabetic patients taking metformin sometimes live longer than non-diabetic people who take nothing, an effect that should not be possible if metformin were doing nothing beyond glucose control. This observation led to the TAME trial — Targeting Aging with Metformin — designed to test whether metformin can delay the onset of multiple age-related diseases simultaneously in non-diabetic older adults.

Rapamycin, originally developed as an immunosuppressant for organ transplant patients, works through a related pathway, inhibiting mTOR. In mice, it reliably extends lifespan by 9 to 14 percent when started in middle age, one of the most consistently reproduced findings in all of aging biology.

A newer pharmacological direction targets telomerase directly. In 2024, a team led by Ronald DePinho at the MD Anderson Cancer Center screened 653,000 compounds and identified one, dubbed a TERT-activating compound or TAC, that boosted the telomere-extending enzyme telomerase throughout the body, including the brain, and reversed numerous signs of aging in mice. It remains a preclinical, animal-stage finding.

The honest caveat matters as much as the promise. As of 2026, no completed human trial has proven that any of these drugs extends healthy lifespan in people without an underlying condition. The case for diabetics and organ transplant patients is much stronger than the case for preventive use in otherwise healthy adults.

Why the FDA Does Not Recognise “Aging” as a Disease

There is a regulatory obstacle sitting underneath every claim in this article that rarely makes the headlines, but shapes the entire field’s strategy.

The U.S. Food and Drug Administration does not currently recognise aging itself as a disease or condition that a drug can be approved to treat. This is precisely why the TAME trial measures metformin’s effect on delaying multiple specific diseases of aging, rather than aging as a single outcome, and why Life Biosciences’ partial reprogramming trial is officially framed around treating glaucoma and NAION, not reversing aging broadly.

Researchers and advocacy organisations, including the American Federation for Aging Research, have spent years lobbying regulators to accept “delayed onset of multiple age-related conditions” as a legitimate trial endpoint, because no existing pathway lets a company seek approval for an anti-aging drug as such.

This gap explains an otherwise puzzling pattern: nearly every legitimate reverse aging therapy currently in human trials is technically being tested against a single named disease — optic nerve damage, type 2 diabetes risk, or organ transplant rejection — even when the scientists running the trial are explicitly motivated by aging biology more broadly. Until that changes, the clinical proof of any reverse aging method will keep arriving sideways, through diseases, rather than head-on.

Epigenetic Clocks: How a “Younger” Result Is Measured

Every claim of reversed biological age in this article rests on a specific measurement tool, and understanding what these tools do and do not capture is essential to reading the evidence correctly.

The original epigenetic clock, developed by biostatistician Steve Horvath in 2013, estimates biological age by examining DNA methylation patterns at several hundred specific sites across the genome. Methylation, a chemical tag attached to DNA that influences gene activity, changes predictably enough with age that Horvath’s clock can estimate a person’s age from a tissue sample to within a few years.

Later clocks refined the idea. GrimAge, from Horvath’s own team, was trained to predict mortality risk. PhenoAge incorporates blood biomarkers. DunedinPACE, used by Bryan Johnson and built from New Zealand’s long-running Dunedin cohort study, measures the pace of aging directly, in biological years accumulated per calendar year.

These tools are genuinely powerful, validated against real health outcomes across large populations. They are not infallible rulers. Different clocks can disagree on the same blood sample, and a clock trained on one population does not always generalise to another. A favourable reading on one clock is informative, but it is not the same as proof that a person’s actual risk of disease or death has dropped by an equivalent margin.

How to Evaluate Reverse Aging Claims You Encounter Online

Given how much money, ego, and genuine hope rides on this field, it is worth equipping yourself with the same questions researchers use to separate signal from noise.

First, ask whether the claim comes from a single self-reported case or from a controlled trial with a comparison group. Elizabeth Parrish’s telomere result and Bryan Johnson’s biological age scores are both single-subject data points. They are interesting. They are not evidence that the same protocol would work in you.

Second, check whether the researchers or company behind a study have a direct financial stake in its outcome, as with the Tel Aviv HBOT trial and several commercial epigenetic-clock providers. A conflict of interest does not make a result wrong, but it does mean independent replication matters more than usual.

Third, distinguish between animal results and human results. Rapamycin’s lifespan extension in mice is one of the most reproduced findings in aging biology. Whether it extends healthy lifespan in humans without an underlying disease remains, as of 2026, genuinely unproven.

Fourth, be aware that even celebrated researchers attract serious scientific pushback. David Sinclair’s bestselling book Lifespan has been praised by some researchers and criticised by others, including biochemist Charles Brenner and University of Alabama biologist Steven Austad, for what they describe as excessive claims. This kind of open disagreement is not a reason to dismiss the field. It is a sign the field is functioning as science should, with claims facing real scrutiny.

Why “Reversing” Aging Is Different From Slowing It

It is worth being precise about a distinction that often gets blurred in headlines, because it changes what each intervention is actually claiming to do.

Slowing aging means reducing the rate at which biological damage accumulates going forward. Reversing aging means actively undoing damage that has already accumulated, moving a measured biomarker backward rather than simply flattening its future trajectory.

Caloric restriction and rapamycin are best understood, on current evidence, as primarily slowing interventions. Partial reprogramming, the transcription-factor approach, HBOT’s telomere effects, and plasma dilution are the candidates with the strongest direct evidence of genuine reversal on specific biomarkers, which is precisely why they generate the most excitement and the most scrutiny at once.

None of this happens in isolation from the underlying genetics. The epigenetic machinery that partial reprogramming targets is the same machinery explored in our article on epigenetics and gene expression. The senescent cells that HBOT and senolytics both target are the same cells discussed in our coverage of telomeres and cellular aging. Reverse aging research is not a separate field from genetics. It is genetics, applied with a specific, audacious goal in mind.

Key Numbers

What Scientists Say

Every quote below is reproduced verbatim from a primary, verifiable source, with the precise origin given for each.

“Until recently, the best we could do was slow aging. New discoveries suggest we can now reverse it.”
— David A. Sinclair, Harvard Medical School. Harvard / Aging press release, 12 July 2023.

“Today telomere shortening is considered the ‘Holy Grail’ of the biology of aging.”
— Shai Efrati, Tel Aviv University. Sagol Center press release, 18 November 2020.

“By altering gene expression using the transcription factors we identified, old fibroblasts behaved as if they were younger, and improved the health of old mice.”
— Hao Li, University of California, San Francisco. NIH Research Matters, 3 March 2026.

Beyond the verbatim record, the field’s leading figures converge on a shared framing. Sinclair describes his work through what he calls the information theory of aging, the idea that aging is fundamentally a loss of epigenetic information rather than damage to the DNA sequence itself, and that this lost information can, in principle, be restored. Irina Conboy’s plasma-dilution work led her to a conclusion that runs against decades of young-blood mythology: that it is not what young blood adds that matters, but what old blood accumulates. And Carlos López-Otín’s hallmarks framework underlies the growing consensus that the most powerful interventions will combine several approaches at once, rather than betting everything on a single miracle.

Frequently Asked Questions

Sources

Primary peer-reviewed research:

1. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243–278. doi.org/10.1016/j.cell.2022.11.001
2. Lu, Y. et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588, 124–129. doi.org/10.1038/s41586-020-2975-4
3. Yang, J. H. et al., Sinclair Lab (2023). Chemically induced reprogramming to reverse cellular aging. Aging, 15. PMC10373966
4. Deng, C., Villeda, S. A., Li, H. et al. (2026). Transcription factors that restore youthful gene expression. PNAS, published 9 January 2026. NIH Research Matters summary
5. Hachmo, Y., Hadanny, A., Abu Hamed, R. … Efrati, S. (2020). Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells. Aging, 12. doi.org/10.18632/aging.202188
6. Brandhorst, S., Levine, M. E. … Longo, V. D. (2024). Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications, 15. doi.org/10.1038/s41467-024-45260-9
7. Andrews, C. et al. (2026). Dietary change and biological age reduction in adults aged 65–75. Aging Cell. University of Sydney summary
8. Mehdipour, M., Skinner, C., Wong, N. … Conboy, I. (2020). Rejuvenation of three germ-layer tissues by exchanging old blood plasma with saline-albumin. Aging, 12. PMC7288913
9. Kim, D., Kiprov, D. D. … Conboy, I. (2022). Old plasma dilution reduces human biological age: a clinical study. GeroScience, 44(6), 2701–2720. doi.org/10.1007/s11357-022-00645-w
10. Fuentealba, M. et al. (2025). Multi-omics analysis of biological age rejuvenation in response to therapeutic plasma exchange. Aging Cell. doi.org/10.1111/acel.70103
11. Castner, S. A. et al. (2023). Longevity factor klotho enhances cognition in aged nonhuman primates. Nature Aging, 3(8), 931–937. doi.org/10.1038/s43587-023-00441-x

Institutional and science journalism coverage:

12. NIH Research Matters (March 2026) — Manipulating Gene Activity to Reverse Aging
13. Nature (April 2026) — This Method to Reverse Cellular Ageing Is About to Be Tested in Humans
14. Live Science (2024) — Single Molecule (TAC) Reverses Signs of Aging in Mice (DePinho, MD Anderson)
15. American Federation for Aging Research — The TAME Trial: Targeting Aging with Metformin
16. American Council on Science and Health (Feb 2025) — Dissecting the Claims of the Blueprint Protocol